0001493152-26-044971.txt : 20260929 0001493152-26-044971.hdr.sgml : 20260929 20260929214740 ACCESSION NUMBER: 0001493152-26-044971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260929 FILED AS OF DATE: 20260929 DATE AS OF CHANGE: 20260929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vasanthavada Madhav CENTRAL INDEX KEY: 0002106295 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15771 FILM NUMBER: 261425356 MAIL ADDRESS: STREET 1: 6555 CARNEGIE AVENUE STREET 2: FLOOR 4 CITY: CLEVELAND STATE: OH ZIP: 44103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ABEONA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000318306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 830221517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 BUSINESS PHONE: 646-813-4701 MAIL ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 FORMER COMPANY: FORMER CONFORMED NAME: PLASMATECH BIOPHARMACEUTICALS INC DATE OF NAME CHANGE: 20140922 FORMER COMPANY: FORMER CONFORMED NAME: ACCESS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960209 FORMER COMPANY: FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml 4 X0609 4 2026-09-29 0 0000318306 ABEONA THERAPEUTICS INC. ABEO 0002106295 Vasanthavada Madhav false 6555 CARNEGIE AVE., 4TH FLOOR CLEVELAND OH 44103 0 1 0 0 Chief Commercial Officer 0 Common Stock 2026-09-29 4 S 0 4902 5.1556 D 285721 D The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1150 to $5.3000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Joseph Vazzano, Attorney-in-Fact 2026-09-29